Jordyn Sava is an editor for Targeted Oncology.
Elacestrant Improves PFS Over SOC in Advanced ER-Positive, HER2-Negative Metastatic Breast Cancer
March 4th 2022Elacestrant demonstrates statistically significant and clinically meaningful improvement in progression-free survival for patients with ER–positive, HER2-negative mBC who previously received CDK4/6 inhibition.
DKN-01 Triplet Shows Encouraging Early Efficacy/Safety in Frontline Gastroesophageal Adenocarcinoma
March 1st 2022Findings show DKN-01, tislelizumab, and capecitabine/oxaliplatin (CAPOX) combination to be well tolerated and have encouraging clinical activity as frontline treatment of patients with advanced gastroesophageal adenocarcinoma.
MARIPOSA Trial to Examine How Amivantamab Plus Lazertinib Compares With Osimertinib in EGFR+ NSCLC
February 24th 2022The MARIPOSA study seeks to assess efficacy, safety, and pharmacokinetics of the combination of amivantamab-vmjw and lazertinib in locally advanced, or metastatic non-small cell lung cancer.
First PSMA PET Set to Improve Imaging in the Prostate Cancer Field
February 15th 2022In an interview with Targeted Oncology, Bridget Koontz, MD, United States chief medical officer and deputy global chief medical officer at GenesisCare, discusses 18F-DCFPyL and how the well-tolerated agent can change the way prostate cancer patients are treated
Positive Results Correlate With Use of Darolutamide in nmCRPC
February 10th 2022In an interview with Targeted Oncology, Neal Shore discusses the findings of ARAMIS which looked at darolutamide in men with high-risk non-metastatic castration-resistant prostate cancer, and its primary end point of metastasis-free survival.
KEYNOTE-522 Shows Prolonged EFS With Adjuvant Pembrolizumab in High-Risk, Early-Stage TNBC
February 10th 2022In KEYNOTE-522, treatment with adjuvant pembrolizumab following neoadjuvant pembrolizumab with chemotherapy showed a statistically significant prolonged event-free survival in patients with high-risk early-stage triple-negative breast cancer.